1. Eli Lilly and Company. TALTZ(TM) (ixekizumab): US prescribing information. Indianapolis: Eli Lilly and Company; 2016.
2. European Medicine Agency. CHMP summary of positive opinion for Taltz 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003943/WC500202360.pdf . Accessed 29 Feb 2016.
3. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–54.e9.
4. Duffin KC, Bagel J, Bukhalo M, et al. Comparison of the pharmacokinetics of ixekizumab following subcutaneous administration using a prefilled syringe versus an autoinjector in patients with moderate-to-severe psoriasis over 12 weeks [abstract no. 2857 plus poster]. In: 74th Annual Meeting of the American Academy of Dermatology; 2016.
5. Gordon K, Blauvelt A, Langley R, et al. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1) [abstract no. F010]. In: American Academy of Dermatology; 2015.